Literature DB >> 2701287

The role of adenosine triphosphate in migraine.

G Burnstock1.   

Abstract

Classical migraine is associated with two distinct phases; an initial vasoconstriction followed by vasodilatation. The "purinergic" hypothesis for migraine was originally put forward in 1981 as a basis for the reactive hyperaemia and pain during the headache phase. It was suggested that adenosine 5'-triphosphate (ATP) and its breakdown products adenosine 5'-monophosphate and adenosine were strong contenders for mediating the vasodilatation following the initial vasospasm and subsequent hypoxia. ATP was also implicated in the pathogenesis of pain during migraine via stimulation of primary afferent nerve terminals located in the cerebral vasculature. Recent studies have shown that the ATP-induced cerebral vasodilation is endothelium-dependent via activation of P2Y-purinoceptors on the endothelial cell surface and subsequent release of endothelium-derived relaxing factor (EDRF); and that the endothelial cells are the main local source of the ATP involved, although adenosine 5'-diphosphate and ATP released from aggregating platelets may also contribute to this vasodilatation. These findings have extended the "purinergic" hypothesis for migraine in two ways. Firstly, they have clarified the mechanism of purinergic vasodilatation during the headache phase of migraine. Secondly, they suggest that a purinergic mechanism may also be involved in the initial local vasospasm, via P2X-purinoceptors on smooth muscle cells occupied by ATP released either as a cotransmitter with noradrenaline from perivascular sympathetic nerves or from damaged endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2701287     DOI: 10.1016/0753-3322(89)90161-3

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

Review 1.  Sumatriptan: efficacy and contribution to migraine mechanisms.

Authors:  J M Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154

Review 2.  Recent patents on novel P2X(7) receptor antagonists and their potential for reducing central nervous system inflammation.

Authors:  Scott A Friedle; Marjorie A Curet; Jyoti J Watters
Journal:  Recent Pat CNS Drug Discov       Date:  2010-01

Review 3.  Caffeine and headaches.

Authors:  Robert E Shapiro
Journal:  Curr Pain Headache Rep       Date:  2008-08

4.  Nucleotide homeostasis and purinergic nociceptive signaling in rat meninges in migraine-like conditions.

Authors:  Gennady G Yegutkin; Cindy Guerrero-Toro; Erkan Kilinc; Kseniya Koroleva; Yevheniia Ishchenko; Polina Abushik; Raisa Giniatullina; Dmitriy Fayuk; Rashid Giniatullin
Journal:  Purinergic Signal       Date:  2016-07-01       Impact factor: 3.765

5.  P2 receptors in cardiovascular regulation and disease.

Authors:  David Erlinge; Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2007-09-21       Impact factor: 3.765

Review 6.  The role of purinergic signaling in the etiology of migraine and novel antimigraine treatment.

Authors:  Marek Cieślak; Joanna Czarnecka; Katarzyna Roszek; Michał Komoszyński
Journal:  Purinergic Signal       Date:  2015-05-10       Impact factor: 3.765

Review 7.  Introduction and perspective, historical note.

Authors:  Geoffrey Burnstock
Journal:  Front Cell Neurosci       Date:  2013-11-21       Impact factor: 5.505

Review 8.  Role of purinergic receptors in the Alzheimer's disease.

Authors:  Marek Cieślak; Andrzej Wojtczak
Journal:  Purinergic Signal       Date:  2018-10-25       Impact factor: 3.765

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.